The anti-fatigue floor mat integrates various functions: fatigue relief, high elasticity, shockproof, etc., can effectively prevent impact and fatal injuries, and is very durable for industrial and harsh environments. The shape of its bottom and surface is designed for workers to stand for a long time, which can greatly reduce the fatigue and pain caused by prolonged standing on the legs. Welcome to visit us. Non Slip pvc Floor Mats,Non-slip Floor Mats,Anti Slip Mats,Non Slip Pvc Mats Jiangyin Yining E-Commerce Co., Ltd , https://www.pvcmatyining.com
Here we recommend our Pvc floor mats, it was widely used for runners of hotel public, we have 1.3mm and 2.5mm two type online produce. welcome to contact us.
1
1.3mm
General type
2
2.5mm
High quality
Hand-foot-mouth vaccine test will effectively prevent hand-foot-mouth disease
Last week, a reporter learned that the results of Phase III clinical trials for the hand-foot-and-mouth disease (HFMD) vaccine have shown an impressive 95% efficacy rate. This breakthrough suggests that once approved, the vaccine could significantly reduce the impact of HFMD, a long-standing concern for both children and their parents.
According to recent reports, the Phase III trial for the EV71 vaccine officially began last year on January 6th. Over 10,000 infants were vaccinated, and after one year, researchers observed strong epidemiological protection. The study found that three consecutive doses of the EV71 vaccine provided excellent immunity in children aged 6 months to 5 years, with good safety profiles. HFMD is a common infectious disease among young children, typically peaking during the summer season. Due to frequent outbreaks in kindergartens, the vaccine requires two doses. It's expected to be approved for market later this year. However, it's still unclear whether it will be included in the national immunization program. Once available, its price is likely to follow that of Class II vaccines.
Although HFMD is preventable and treatable, there has been no effective vaccine for EV71 infection globally until now. In the absence of effective treatments or widely available vaccines, experts warn that the disease may remain a significant public health challenge. Zeng Guang, chief scientist at the Chinese Center for Disease Control and Prevention, emphasized that without a successful vaccine, HFMD will continue to spread rapidly in the coming period.
The EV71 vaccine developed by Beijing Kexing Bio-products Co., Ltd. is produced using African monkey kidney cells, with the virus cultured, harvested, inactivated, purified, and adsorbed onto aluminum. The clinical trial version of the vaccine has already passed testing by the China Food and Drug Testing Institute. The company is preparing for the next phase of trials. Yin Weidong, head of vaccine development, explained that the earlier trials focused on safety and effectiveness, while the upcoming Phase III trials will focus on the vaccine’s epidemiological protective effect and long-term immunity.